Castle Biosciences Inc. Chief Commercial Officer Tobin W Juvenal filed a Form 4 on November 13, 2026, disclosing the exercise of stock options and sale of 3,195 shares of common stock on November 11, 2026.

Key Highlights

  • Option exercise: Juvenal acquired 3,195 shares of common stock via stock option exercise (transaction code M) at an exercise price of $29.50 per share on November 11, 2026.
  • Shares sold: 3,195 shares were disposed of (transaction code S) at a weighted-average price of $35.07 per share on November 11, 2026.
  • Sale price range: According to the filing, the transaction was executed in multiple trades at prices ranging from $35.04 to $35.11, inclusive.
  • Remaining direct holdings: Following the transactions, Juvenal directly owned 32,737 shares of common stock.
  • Remaining options: Juvenal retains 31,805 shares underlying a fully vested stock option with an exercise price of $29.50 and an expiration date of December 12, 2029.
  • Issuer: Castle Biosciences Inc., listed on NASDAQ:CSTL.

Juvenal's Option Exercise and Share Sale at Castle Biosciences

According to the Form 4 filed with the SEC on November 13, 2026, Tobin W Juvenal, serving as Chief Commercial Officer of Castle Biosciences Inc. (NASDAQ:CSTL), reported two transactions in the company's common stock, both dated November 11, 2026. The first was the exercise of a stock option (transaction code M) covering 3,195 shares at an exercise price of $29.50 per share, bringing his directly held common stock to 35,932 shares following that acquisition.

Immediately following the exercise, the filing discloses that Juvenal disposed of 3,195 shares (transaction code S) at a weighted-average sale price of $35.07 per share. The filing notes that the sale was executed across multiple trades at prices ranging from $35.04 to $35.11, inclusive. After this disposal, his direct beneficial ownership in Castle Biosciences common stock stood at 32,737 shares, according to the filing.

In Table II, the filing reports that the stock option from which the 3,195 shares were drawn carried an exercise price of $29.50 and is described as fully vested. Following the partial exercise, 31,805 shares remain underlying that option, which carries an expiration date of December 12, 2029. The filing was signed by Frank Stokes as attorney-in-fact for the reporting person on November 13, 2026.

What Was Disclosed

Castle Biosciences CCO Tobin W Juvenal disclosed the exercise of a fully vested stock option for 3,195 shares at $29.50 and the same-day sale of those shares at a weighted-average price of $35.07, leaving him with 32,737 shares of common stock held directly.